Use of the prophylactic implantable cardioverter defibrillator for patients with normal hearts
- PMID: 10089849
- DOI: 10.1016/s0002-9149(98)01009-1
Use of the prophylactic implantable cardioverter defibrillator for patients with normal hearts
Abstract
About 10-20% of patients dying suddenly and unexpectedly do not have structural heart disease. The major causes of sudden death in this population are acute ischemia, the syndrome of right bundle branch block, and ST-elevation from V1 to V3, the long QT-syndrome, and the Wolff-Parkinson-While syndrome. In some patients, none of these syndromes can be recognized and ventricular fibrillation is classified as idiopathic. There are good preventive and therapeutic methods against acute ischemia and there are also curative treatments for the Wolff-Parkinson-White syndrome. Patients with idiopathic ventricular fibrillation cannot be recognized beforehand. However, there are electrocardiographic and genetic markers for the Brugada syndrome and the long QT syndrome. It is, therefore, justified to discuss the possible role of the prophylactic defibrillator to prevent sudden death in these 2 syndromes for which no effective treatment exists. Patients with Brugada syndrome have a high incidence of sudden death, and prophylactic defibrillators are indicated in patients with inducible arrhythmias at electrophysiologic study, irrespective of symptoms. On the contrary, the incidence of sudden death in the long QT syndrome is very low, making prophylactic defibrillator implantation not cost-effective.
Similar articles
-
Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders.Heart Rhythm. 2013 Oct;10(10):1492-8. doi: 10.1016/j.hrthm.2013.06.020. Epub 2013 Jun 26. Heart Rhythm. 2013. PMID: 23811080
-
Brugada and long QT-3 syndromes: two phenotypes of the sodium channel disease.Ann Noninvasive Electrocardiol. 2004 Jul;9(3):280-9. doi: 10.1111/j.1542-474X.2004.93533.x. Ann Noninvasive Electrocardiol. 2004. PMID: 15245345 Free PMC article. Review.
-
What is the Brugada syndrome?Cardiol Rev. 1999 Jul-Aug;7(4):191-5. doi: 10.1097/00045415-199907000-00010. Cardiol Rev. 1999. PMID: 10423670 Review.
-
[Right bundle branch block and ST-segment elevation in right precordial leads: a marker for sudden cardiac death].Orv Hetil. 2000 Mar 19;141(12):615-7. Orv Hetil. 2000. PMID: 10769545 Hungarian.
-
Right bundle-branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease.Circulation. 1998 Feb 10;97(5):457-60. doi: 10.1161/01.cir.97.5.457. Circulation. 1998. PMID: 9490240
Cited by
-
QT Prolongation and Malignant Arrhythmia: How Serious a Problem?Eur Cardiol. 2017 Dec;12(2):112-120. doi: 10.15420/ecr.2017:16:1. Eur Cardiol. 2017. PMID: 30416582 Free PMC article. Review.
-
Cardiovascular adverse effects of antipsychotic drugs.Drug Saf. 2000 Sep;23(3):215-28. doi: 10.2165/00002018-200023030-00004. Drug Saf. 2000. PMID: 11005704 Review.
-
Fever associated with gastrointestinal shigellosis unmasks probable brugada syndrome.Case Rep Med. 2009;2009:492031. doi: 10.1155/2009/492031. Epub 2009 Dec 24. Case Rep Med. 2009. PMID: 20069106 Free PMC article.
-
Brugada syndrome in childhood: a potential fatal arrhythmia not always recognised by paediatricians. A case report and review of the literature.Eur J Pediatr. 2006 Aug;165(8):507-11. doi: 10.1007/s00431-006-0150-z. Epub 2006 May 3. Eur J Pediatr. 2006. PMID: 16670860 Review.
-
Sodium channel current loss of function in induced pluripotent stem cell-derived cardiomyocytes from a Brugada syndrome patient.J Mol Cell Cardiol. 2018 Jan;114:10-19. doi: 10.1016/j.yjmcc.2017.10.002. Epub 2017 Oct 9. J Mol Cell Cardiol. 2018. PMID: 29024690 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
